Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 8/20 | 0.57 |
| ▸ | TPO | P07202 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | GRK6 | P43250 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14936492 | 0.83 | MPO (0.56) | MPOTPOALDH1A1KDM4EMTNR1A | |
| SCHEMBL14936348 | 0.83 | MPO (0.58) | MPOTPOALDH1A1KDM4EMTNR1A | |
| SCHEMBL14936166 | 0.81 | MPO (0.76) | MPOTPOALDH1A1KDM4EKMT2A | |
| SCHEMBL14936385 | 0.79 | MPO (0.47) | MPOTPOALDH1A1KDM4EMTNR1A | |
| SCHEMBL14946996 | 0.77 | MPO (0.53) | MPOTPOALDH1A1KDM4EMTNR1A | |
| SCHEMBL14935988 | 0.76 | MPO (0.72) | MPOTPOALDH1A1KMT2AMEN1 | |
| SCHEMBL14947070 | 0.76 | MPO (0.60) | MPOTPO | |
| SCHEMBL14935957 | 0.76 | MPO (0.69) | MPOTPOALDH1A1MAPTGAA | |
| SCHEMBL14936384 | 0.76 | MPO (0.75) | MPOTPOALDH1A1KDM4EMTNR1A | |
| SCHEMBL14936194 | 0.76 | MPO (0.60) | MPOTPOALDH1A1KDM4EMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873673-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873673-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160304469-A1 | 2-Thiopyrimidinones | PFIZER INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160304469-A1 | 2-Thiopyrimidinones | PFIZER INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-9399626-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-9399626-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-20140288049-A1 | 2-Thiopyrimidinones | PFIZER (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288049-A1 | 2-Thiopyrimidinones | PFIZER (US) | 2014-09-25 | — | — | US | disclosed |
| US-8841314-B2 | 2-Thiopyrimidinones | PFIZER INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841314-B2 | 2-Thiopyrimidinones | PFIZER INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8835449-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835449-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20130296351-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130296351-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130123230-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-05-16 | — | — | US | disclosed |
| US-20130123230-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123230-A1 | 2-Thiopyrimidinones | MPO, SERPINB1, TNNI3 | MPO 1/4885TPO 32/4885ALDH1A1 280/4885 |
| US-20160304469-A1 | 2-Thiopyrimidinones | MPO, SERPINB1, TNNI3 | MPO 1/4885TPO 32/4885ALDH1A1 280/4885 |
| US-20140288049-A1 | 2-Thiopyrimidinones | MPO, SERPINB1, TNNI3 | MPO 1/4885TPO 32/4885ALDH1A1 280/4885 |
| US-20130296351-A1 | 2-Thiopyrimidinones | MPO, SERPINB1, TNNI3 | MPO 1/4885TPO 32/4885ALDH1A1 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.